GHRP-2
Also known as: Pralmorelin
GHRP-2 is a synthetic growth hormone releasing peptide and ghrelin-mimetic studied in early research for its reported ability to stimulate growth hormone release. It is not approved for human use in Australia.
- Category
- Growth Hormone Secretagogue
- Reported half-life
- Reported ~15-60 minutes (varies by study)
- Common forms
- Lyophilised powder for reconstitution, Injectable solution
- Research status
- Not approved for human use in Australia; investigated in research and diagnostic contexts only (e.g. as a growth hormone stimulation test in some countries). No marketed general therapeutic product.
- Last updated
- 21 June 2026
Claimed effects
The following effects are reported or claimed by users and in early research. They are not established medical facts and many are not supported by large human trials.
- Reported to stimulate a pulse of growth hormone release
- Studied as a diagnostic stimulus for growth hormone secretion
- Users report increased appetite via ghrelin-receptor activity
- Early research indicates possible rises in IGF-1
How it is reported to work
GHRP-2 is reported to mimic ghrelin and act on the growth hormone secretagogue receptor of the pituitary and hypothalamus, prompting a pulse of growth hormone release. It is also reported to stimulate appetite through the same receptor. These descriptions come from early clinical and diagnostic research and are not established for general use.
Background
GHRP-2 (pralmorelin) is a synthetic growth hormone releasing peptide - a ghrelin-mimetic reported to prompt growth hormone release from the pituitary. In some countries it has been used as a diagnostic stimulus to test growth hormone secretion. This page is educational information, not medical advice, and the effects below are claimed rather than established for general use.
What the research actually shows
GHRP-2 has been examined in early-stage and diagnostic research, where it is reported to trigger growth hormone release. Large, long-term human trials supporting general benefit and safety are lacking, and appetite effects mean reported “body composition” claims are nuanced.
| Evidence type | Status |
|---|---|
| Early/diagnostic research | Present |
| Large general-use trials | Lacking |
| Australian approval | None |
What people use it for (reported)
Online, people report using GHRP-2 in attempts to support recovery and body composition, and note its reported appetite-stimulating effect. These are anecdotal reports, not validated results. Studies suggest the mechanism involves the growth hormone secretagogue receptor.
Things to be aware of
GHRP-2 is not approved for human use in Australia. Manipulating growth hormone and appetite pathways can have unintended effects, and grey-market product purity cannot be verified by sight.
If you have a health concern, the appropriate step is to talk to a qualified healthcare professional rather than self-experimenting. This article is not an endorsement and does not recommend obtaining or using GHRP-2.
Reported positives & side effects
Compiled from research and community reports. These are reported outcomes, not guarantees or medical advice, individual experiences vary widely.
Reported positives
- Reported to stimulate a strong pulse of growth-hormone release
- Used in research as a diagnostic stimulus for growth-hormone secretion
- Users report improved recovery and sleep
- Reported increase in appetite via ghrelin-receptor activity
- Reported possible rises in IGF-1 over time
Common side effects
- Increased appetite or hunger
- Injection-site reactions such as redness or itching
- Facial flushing or head-rush after injection
- Water retention or puffiness
- Tingling or numbness in the hands
Rare / serious side effects
- Raised prolactin or cortisol reported with higher doses in some studies
- Changes in blood-sugar control
- Allergic-type reactions
- Reactions attributed to impurities in unregulated grey-market product
Reported misuse & overdose risks
What has been reported to happen with overuse, excessive dosing, or long-term misuse of GHRP-2. Listed so you can make an informed decision, not to suggest any use is safe.
- Higher doses are reported to raise prolactin and cortisol, unlike more selective secretagogues, which is a frequently cited reason against overuse
- Chronic high-dose use is reported to risk down-regulating the body's own growth-hormone pulses, suppressing natural production over time
- Strong appetite stimulation is reported to drive unwanted overeating and weight gain when overused
- Sustained growth-hormone and IGF-1 elevation from overuse is reported to risk insulin resistance, fluid retention and theoretical concern about abnormal tissue growth
- Unverified grey-market product is reported to risk contamination and incorrect dosing
Reported results timeline
Roughly how long people report it takes to notice effects. A general guide from reports, not a promise, and not advice. Appetite and sleep effects are often reported within days, while body-composition changes are reported to build over several months.
First effects
Appetite and sleep changes within days
Noticeable change
Recovery and well-being ~4 weeks
Clear results
Body-composition changes ~12 weeks
Peak effect
Fuller effects reported ~16-20 weeks
Commonly reported dosing & protocol
Reported figures only, NOT a recommendation or dosing advice. These are numbers people report using, compiled for education so you can make an informed decision. We do not advise anyone to take GHRP-2. Many peptides are not approved for human use in Australia. Speak to a qualified healthcare professional.
| Route | Subcutaneous injection |
|---|---|
| Typical reported dose | Reported community figures of roughly 100–300 mcg per dose (often paired with a GHRH analogue) |
| Frequency | Reported as 1–3× daily |
| Cycle length | Reported cycles of about 8–12 weeks, then a break |
Reported reconstitution (mg → units)
Worked example only: a 5 mg vial + 2 mL bacteriostatic water = 2.5 mg/mL. A 100 mcg (0.1 mg) dose ≈ 0.04 mL = 4 units on a U-100 insulin syringe; a 300 mcg (0.3 mg) dose ≈ 0.12 mL = 12 units.
Work out the units for your vial → CalculatorCommonly reported community patterns describe one or more daily injections, often timed before bed or training and paired with a GHRH analogue, run in cycles of roughly 8 to 12 weeks with a break. These are reported patterns only, not a recommendation, and GHRP-2 is not approved for human use in Australia.
Best used with / commonly stacked with
Combinations people report using together. Reported, not recommended, stacking can increase risks.
Classic reported pairing of a ghrelin-mimetic with a GHRH analogue to amplify the growth-hormone pulse
Reported as an alternative GHRH-analogue partner
Reported as a more selective ghrelin-mimetic users rotate to for fewer prolactin effects
Safety notes
GHRP-2 is not approved by the TGA for human use in Australia, and long-term human safety data is lacking. Stimulating growth hormone and appetite pathways can carry risks, and grey-market product purity cannot be verified by consumers. Anyone considering it should first consult a qualified healthcare professional.